TW201900671A - 使用可溶性cd24進行神經保護及髓鞘再生的方法 - Google Patents
使用可溶性cd24進行神經保護及髓鞘再生的方法 Download PDFInfo
- Publication number
- TW201900671A TW201900671A TW107116447A TW107116447A TW201900671A TW 201900671 A TW201900671 A TW 201900671A TW 107116447 A TW107116447 A TW 107116447A TW 107116447 A TW107116447 A TW 107116447A TW 201900671 A TW201900671 A TW 201900671A
- Authority
- TW
- Taiwan
- Prior art keywords
- hours
- protein
- cd24fc
- minutes
- mice
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 title claims description 142
- 102100038081 Signal transducer CD24 Human genes 0.000 title claims description 124
- 230000004112 neuroprotection Effects 0.000 title description 4
- 210000004498 neuroglial cell Anatomy 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 201000006417 multiple sclerosis Diseases 0.000 claims description 20
- 102000044489 human CD24 Human genes 0.000 claims description 18
- 102000006386 Myelin Proteins Human genes 0.000 claims description 16
- 108010083674 Myelin Proteins Proteins 0.000 claims description 16
- 210000005012 myelin Anatomy 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 11
- 230000003210 demyelinating effect Effects 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 208000003435 Optic Neuritis Diseases 0.000 claims description 6
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 6
- 208000010396 acute flaccid myelitis Diseases 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 6
- 230000001177 retroviral effect Effects 0.000 claims description 6
- 208000009174 transverse myelitis Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 230000010307 cell transformation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 12
- 208000016192 Demyelinating disease Diseases 0.000 abstract description 9
- 210000004248 oligodendroglia Anatomy 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 description 62
- 230000027455 binding Effects 0.000 description 56
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 48
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 47
- 102000004856 Lectins Human genes 0.000 description 41
- 108090001090 Lectins Proteins 0.000 description 41
- 239000002523 lectin Substances 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 30
- 235000001014 amino acid Nutrition 0.000 description 29
- 210000003169 central nervous system Anatomy 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 26
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 230000004044 response Effects 0.000 description 20
- 102000037865 fusion proteins Human genes 0.000 description 19
- 108020001507 fusion proteins Proteins 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 201000002491 encephalomyelitis Diseases 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 230000008929 regeneration Effects 0.000 description 13
- 238000011069 regeneration method Methods 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 101150082143 CD24 gene Proteins 0.000 description 10
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 10
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000000451 tissue damage Effects 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 102000055207 HMGB1 Human genes 0.000 description 8
- 108700010013 HMGB1 Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000001703 neuroimmune Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 231100000827 tissue damage Toxicity 0.000 description 8
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 7
- 101150021904 HMGB1 gene Proteins 0.000 description 7
- 101710198418 Lectin 10 Proteins 0.000 description 7
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 6
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000003007 myelin sheath Anatomy 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 101710113864 Heat shock protein 90 Proteins 0.000 description 5
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 5
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 5
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 5
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 5
- 102000002689 Toll-like receptor Human genes 0.000 description 5
- 108020000411 Toll-like receptor Proteins 0.000 description 5
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000006727 cell loss Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000007910 systemic administration Methods 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 4
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- -1 hydrophobicity Chemical class 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 101150082239 G gene Proteins 0.000 description 3
- 102000005803 Oligodendrocyte Transcription Factor 2 Human genes 0.000 description 3
- 108010019644 Oligodendrocyte Transcription Factor 2 Proteins 0.000 description 3
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229960000556 fingolimod Drugs 0.000 description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WIJIRYKVMWGBHO-NXYDILSSSA-N (6r,8r,9s,13s,14s,17s)-6-(6-methoxyhexyl)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound C12=CC=C(O)C=C2[C@H](CCCCCCOC)C[C@@H]2[C@@H]1CC[C@]1(C)[C@@H](O)CC[C@H]12 WIJIRYKVMWGBHO-NXYDILSSSA-N 0.000 description 2
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 239000005947 Dimethoate Substances 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 2
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 2
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 description 2
- 102100021010 Nucleolin Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 101100455946 Rattus norvegicus Mag gene Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 108010044762 nucleolin Proteins 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000003976 synaptic dysfunction Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- HRANPRDGABOKNQ-ORGXEYTDSA-N (1r,3r,3as,3br,7ar,8as,8bs,8cs,10as)-1-acetyl-5-chloro-3-hydroxy-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1[C@H](O)C[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 HRANPRDGABOKNQ-ORGXEYTDSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101710183446 C-type lectin domain family 4 member E Proteins 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
- APSNPMVGBGZYAJ-LYRQQEFTSA-N Clematin Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(OC)c(O)cc4)Oc3c2)O1)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 APSNPMVGBGZYAJ-LYRQQEFTSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 description 1
- 101000616778 Homo sapiens Myelin-associated glycoprotein Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101710197068 Lectin-4 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101000884281 Rattus norvegicus Signal transducer CD24 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 101710150766 Sialic acid-binding lectin Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 102000051756 human MAG Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229950010704 opicinumab Drugs 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000010472 type I IFN response Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506135P | 2017-05-15 | 2017-05-15 | |
| US62/506,135 | 2017-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201900671A true TW201900671A (zh) | 2019-01-01 |
Family
ID=64274583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107116447A TW201900671A (zh) | 2017-05-15 | 2018-05-15 | 使用可溶性cd24進行神經保護及髓鞘再生的方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200181235A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3624838B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2020519627A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20200034957A (cg-RX-API-DMAC10.html) |
| CN (1) | CN110650749A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3063894A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW201900671A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018213266A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130231464A1 (en) | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
| KR102559149B1 (ko) | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| US20230103352A1 (en) * | 2020-02-10 | 2023-04-06 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating sars-cov-2 infection |
| CN116555185A (zh) * | 2023-04-27 | 2023-08-08 | 山东大学 | 一种靶向gpc3阻断免疫抑制信号的car-巨噬细胞及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067110B1 (en) * | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US20030106084A1 (en) * | 2000-03-29 | 2003-06-05 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
| WO2001072325A1 (en) * | 2000-03-29 | 2001-10-04 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive t cells |
| US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
| ES2826445T3 (es) * | 2010-04-28 | 2021-05-18 | Oncolmmune Inc | Uso médico de CD24 soluble |
| US10689447B2 (en) * | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| MX2015004436A (es) * | 2012-10-09 | 2015-06-24 | Biogen Idec Inc | Tratamientos conjuntos y usos para tratar trastornos desmielinizantes. |
-
2018
- 2018-05-15 CN CN201880030068.0A patent/CN110650749A/zh active Pending
- 2018-05-15 EP EP18801838.6A patent/EP3624838B1/en active Active
- 2018-05-15 WO PCT/US2018/032699 patent/WO2018213266A1/en not_active Ceased
- 2018-05-15 JP JP2019562255A patent/JP2020519627A/ja active Pending
- 2018-05-15 CA CA3063894A patent/CA3063894A1/en not_active Abandoned
- 2018-05-15 US US16/613,339 patent/US20200181235A1/en not_active Abandoned
- 2018-05-15 TW TW107116447A patent/TW201900671A/zh unknown
- 2018-05-15 KR KR1020197036774A patent/KR20200034957A/ko not_active Ceased
-
2021
- 2021-09-30 US US17/490,505 patent/US20220098278A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3063894A1 (en) | 2018-11-22 |
| JP2020519627A (ja) | 2020-07-02 |
| US20200181235A1 (en) | 2020-06-11 |
| CN110650749A (zh) | 2020-01-03 |
| EP3624838A4 (en) | 2021-02-24 |
| KR20200034957A (ko) | 2020-04-01 |
| WO2018213266A1 (en) | 2018-11-22 |
| EP3624838B1 (en) | 2023-01-25 |
| US20220098278A1 (en) | 2022-03-31 |
| EP3624838A1 (en) | 2020-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220098278A1 (en) | Methods of Use of Soluble CD24 for Neuroprotection and Remyelination | |
| JP5738333B2 (ja) | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド | |
| JP6364352B2 (ja) | 部分的ｍｈｃコンストラクト及びその使用方法 | |
| US20130095118A1 (en) | Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability | |
| CN107531772A (zh) | Cd24用于降低低密度脂蛋白胆固醇水平的用途 | |
| CA2978526A1 (en) | Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases | |
| US20130011835A1 (en) | Compositions and methods for treating inflammation | |
| US10316075B2 (en) | Recombinant polypeptides comprising MHC class II α1 domains | |
| CN112752766A (zh) | Cd24用于预防和治疗白血病复发的使用方法 | |
| KR20190126801A (ko) | 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법 | |
| JP7511551B2 (ja) | 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法 | |
| WO2008053049A1 (en) | Modulators of cell adhesion molecules and use thereof | |
| WO2017160599A1 (en) | Use of cd300b antagonists to treat sepsis and septic shock | |
| KR20230135556A (ko) | 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| EP3921339A2 (en) | Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes | |
| US20170355755A1 (en) | Compositions and methods for modulating salm5 and hvem | |
| WO2023283381A1 (en) | Suppression of uveitis by single domain antibody | |
| Paltser | Neuro-Immune Elements of Inflammatory Disease | |
| WO2015168786A1 (en) | Method for decreasing retinal ganglion cells degeneration |